Glucotrack Announces Repurchase of Series A Warrants
Provided By GlobeNewswire
Last update: Jul 8, 2025
RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025.
Read more at globenewswire.com
